Advanced Biomed Inc. Common Stock (ADVB) SEC Filings: History & Chart

Advanced Biomed Inc. Common Stock(ADVB)

Medical - Diagnostics & Research · New York City, NY

$6.52+0.17 (+2.76%)

Delayed quote: Oct 6, 2026, 3:37 PM EDT

About Advanced Biomed Inc. Common Stock

Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.

New York City, NY

31 employees

www.advanbiomed.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Xiaomin Chen

View full financials

Form	Filing Date	Accepted	Document
NT 10-K	Sep 28, 2026	Sep 28, 2026	View filing
SC 13G	Sep 22, 2026	Sep 22, 2026	View filing
4	Aug 20, 2026	Aug 20, 2026	View filing
SC 13G/A	Aug 20, 2026	Aug 20, 2026	View filing
SC 13G	Aug 20, 2026	Aug 20, 2026	View filing
RW	Jul 20, 2026	Jul 20, 2026	View filing
8-K	Jul 17, 2026	Jul 17, 2026	View filing
8-K	Jul 1, 2026	Jul 1, 2026	View filing
8-K	Jun 30, 2026	Jun 30, 2026	View filing
DEF 14A	Jun 4, 2026	Jun 4, 2026	View filing
10-Q	May 15, 2026	May 15, 2026	View filing
8-K	May 1, 2026	May 1, 2026	View filing
8-K	Apr 14, 2026	Apr 14, 2026	View filing
8-K	Apr 3, 2026	Apr 3, 2026	View filing
8-K	Mar 30, 2026	Mar 30, 2026	View filing
8-K	Mar 16, 2026	Mar 16, 2026	View filing
8-K	Feb 26, 2026	Feb 26, 2026	View filing
10-Q	Feb 13, 2026	Feb 13, 2026	View filing
8-K/A	Feb 10, 2026	Feb 10, 2026	View filing
8-K	Feb 2, 2026	Feb 2, 2026	View filing
8-K	Jan 27, 2026	Jan 27, 2026	View filing
DEF 14C	Jan 23, 2026	Jan 23, 2026	View filing
8-K	Jan 21, 2026	Jan 21, 2026	View filing
PRE 14C	Jan 12, 2026	Jan 12, 2026	View filing
8-K	Dec 30, 2025	Dec 30, 2025	View filing
10-Q	Nov 19, 2025	Nov 19, 2025	View filing
NT 10-Q	Nov 14, 2025	Nov 14, 2025	View filing
10-K	Oct 8, 2025	Oct 8, 2025	View filing
NT 10-K	Sep 30, 2025	Sep 30, 2025	View filing
8-K	Sep 19, 2025	Sep 19, 2025	View filing

SEC Filings

Recent Filings